Towards routine employment of computational tools for antimicrobial resistance determination via high-throughput sequencing

Simone Marini[1⋆•] Rodrigo A. Mora[1⋆] Christina Boucher[2] Noelle Noyes[3]
Mattia Prosperi[1•]

[1]Department of Epidemiology, University of Florida
{simone.marini, m.prosperi}@ufl.edu
[2]Department of Computer and Information Science and Engineering,
University of Florida
[3]Department of Veterinary Population Medicine,
University of Minnesota
•Corresponding authors
⋆Equal contribution

Abstract

Antimicrobial resistance (AMR) is a growing threat to public health and farming at large. Without appropriate interventions, it can lead to millions of deaths per year and substantial economic loss worldwide. In clinical and veterinary practice, a timely characterization of the antibiotic susceptibility profile of bacterial infections is a crucial step in optimizing treatment. Fast turnaround of AMR testing is also needed in food safety and infection control surveillance (e.g., contamination of healthcare or long-term nursing facilities). High-throughput sequencing is a promising option for clinical point-of-care and ecological surveillance, opening the opportunity to develop genotyping-based AMR determination as a possibly faster alternative to phenotypic testing. In the present work, we compare the performance of state-of-the-art methods for detection of AMR from high-throughput sequencing data in healthcare settings. We consider five complementary computational approaches –alignment (AMRPlusPlus), deep learning (DeepARG), *k*-mer genomic signatures (KARGA, ResFinder), and hidden Markov models (Meta-MARC). We use an extensive collection of clinical studies never employed for model training. To do so, we assemble data from multiple, independent AMR high-throughput sequencing experiments collected in a variety of hospital settings, comprising of 585 isolates with a available AMR resistance profiles determined by phenotypic tests across nine antibiotic classes. We show how the prediction landscape of AMR classifiers is highly heterogeneous, with balanced accuracy varying from 0.4 to 0.92. Although some algorithms—ResFinder, KARGA, and AMRPlusPlus– exhibit overall better balanced accuracy than others, the high per-AMR-class variance and related findings suggest that: (1) all algorithms might be subject to sampling bias present both in data repositories used for training and experimental/clinical settings; and (2) a portion of clinical samples might contain uncharacterized AMR genes that the algorithms—mostly trained on known AMR genes—fail to generalize upon. These results lead us to formulate practical advice for software configuration and application, as well as give suggestions for future study design to further develop AMR prediction tools from proof-of-concept to bedside.

Introduction

Antimicrobial resistance (AMR) occurs when microorganisms evolve to overcome susceptibility to antibiotics. According to the US Centers for Disease Control (CDC), more than 2.8 million antibiotic-resistant infections and over 35,000 resultant deaths occur each year in the US alone[1]. On a national level, it is predicted that AMR-related infections will lead to 10 million deaths per year and a gross domestic product (GDP) loss of $100.2 trillion by 2050 without appropriate interventions [2]. From managing antibiotic misuse in healthcare to regulating their

use in livestock and agriculture, AMR has become an "arms race" between microorganism adaptation and drug discovery. In clinical settings, one major obstacle to optimizing treatment of AMR-related infections is access to accurate and timely antibiotic susceptibility testing (AST)[3]. Wet-lab AST techniques generally require growing bacteria in vitro and testing against various antibiotics. Examples include agar-based culture techniques, disk diffusion, and Etest [4]. These techniques are limited in that: (a) culture conditions have not been validated for every infectious microbial species, and only a fraction of bacterial species are cultivable with standard methods; (b) they may take as long as 5 days hours before the result is obtained (1–3 days for culture and 1-2 days for AST)[3]; (c) result interpretation standards are constantly evolving; and (d) they are resource intensive in terms of training personnel effort, equipment, and consumables.

The widespread use of DNA sequencing technologies has led to the development of curated databases of AMR genes complementing culture experiments, with detailed functional annotation and other metadata[5, 6, 7, 8, 9, 10]. In turn, computational approaches have emerged to provide in silico detection and characterization of AMR phenotypes and genes, processing targeted sequences as well as metagenomic samples from both clinical and environmental settings. These tools can directly process high-throughput short read sequencing data (typically in FASTQ format)[9, 11, 12, 13], or take as input assembled contigs, translated proteins, or whole bacterial genomes (typically FASTA format)[8, 14, 15, 16]. Also, some tools are purposely designed for metagenomics data, while others specialize on specific bacterial species. Despite the promising results shown in literature and support from experimental studies, the uptake of sequencing-based computational AMR prediction tools for routine healthcare has been slow[17]. One of the major roadblocks is that algorithms can exhibit discordant performance in clinical settings, and there is not yet a gold standard or consensus like the Clinical & Laboratory Standards Institute (CLSI) for AST. Sub-problems that impede the development of such gold standard include: (a) possible shifts and bias in species or genus representations when comparing the training settings of models with the application settings[10, 18]; (b) different working assumptions of the tools and required inputs; and (c) choice of biological ontologies for AMR representation, i.e., standardized encoding of AMR agents and mechanisms, and prediction outputs. These problems make it difficult to compare methods in terms of performance, agreement, and generalizability, complicating the establishment of benchmark data sets and external validation. Prior works identified strong spatiotemporal heterogeneity in sampling and species' representation in genotype-phenotype data repositories, confounding the identification of AMR gene signatures, as well as the generalizability of prediction models on independent data[18, 19]. For example, some AMR genes or variants are species-specific, e.g., resistance to fluoroquinolones via the *gyrA* gene is specific to *Mycoplasma genitalium*[20, 9, 15].

From one perspective, AMR detection algorithms operating on whole genomes and using rules for specific bacterial strains have a design advantage with respect to species representation bias. However, requiring a whole genome sequence as input implies that the bacterial strain has been identified prior to sequencing, which excludes unculturable pathogens. Furthermore, software for genome assembly must be run, either de novo or reference-based, with potential downstream errors.

Algorithms which take as input unassembled sequence reads do not need a priori information about the bacterial species in the sample. In addition, metagenomics-based, culture-independent genomic approaches can be used concurrently with the traditional methods to help detect AMR in unculturable bacteria, eliminating the necessity of species isolation [21]. The absence of assembled genomes makes the AMR classification task more challenging, since results must be aggregated from the read to the isolate level, and species-specific AMR rules might need to be embedded in the algorithms. Nonetheless, these algorithms are in principle more flexible and applicable to a variety of clinical scenarios, involving both characterization of known AMR as well as possibly as novel microbial elements or resistance genes.

Regardless of the methodology of operation, all methods are subject to the ontology issues, as there are multiple ontologies for AMR genes and mechanisms, and some tools predict AST phenotypes directly rather than AMR genes.

In this study, we assess the predictive performance of state-of-the-art AMR classification algorithms for high-throughput bacterial sequencing data from clinical settings. We consider different tools that include alignment-based (AMRPlusPlus)[9], k-mer signatures (KARGA, ResFinder)[13, 22], and machine learning (Meta-MARC, DeepARG)[11, 12] methods. We have designed an extensive benchmark setup apt to address agreement and generalizability issues. More specifically, we have collated high-throughput sequencing data from 585 clinical

isolates, sourced from different studies in clinical settings worldwide (Asia, Europe, North America, and South America), all with available phenotypic AST resistance profiles, covering nine major AMR classes. We provide a robust assessment of the algorithms capabilities and discuss the potential future implications for their routine use in healthcare settings.

1 Methods

1.1 AMR algorithms and software

Notwithstanding a very large collection of AMR prediction methods, this study includes approaches that directly take high-throughput sequencing data as input, removing the necessity for genome assembly prior to analysis. We compare the following AMR computational tools: AMRPlusPlus, DeepARG, KARGA, Meta-MARC, and ResFinder. As previously mentioned, these methods use a variety of different computational approaches, i.e. alignment-based, *k*-mer based (*k*-mers are nucleotide signatures of fixed length k), and machine learning. Also, some tools provide predictions at the read level (DeepARG), while others at the isolate level (AMRPlusPlus, ResFinder), or both (KARGA and Meta-MARC). We compare the methods in Table 1.

Tool	Algorithmic approach	AMR database	Whole-sample resistome characterization	Per-read resistome classification	Platform
AMRPlusPlus	Read alignment	MEGARes	✓		UNIX/Linux
Meta-MARC	HMM classification	MEGARes	✓	✓	UNIX/Linux
KARGA	Comparison of *k*-mers	MEGARes, or any other fasta AMR DB	✓	✓	Any with JVM
DeepARG	Read alignment + CNN classification	DeepARG DB		✓	Any with pip, Conda, Docker
ResFinder	*k*-mers + alignment	ResFinder DB + PointFinder DB	✓		Any with Pyhton 3, Docker; Webserver

Table 1: Summary of AMR prediction tools evaluated in this study, describing: algorithmic approach; reference AMR database; output capabilities as whole-sample and/or per-read AMR gene prediction; working platform(s). *HMM*, Hidden Markov models; *CNN* Convolutional neural network; *JVM* Java Virtual Machine.

AMRPlusPlus (v.2.0) is a comprehensive software framework built around the MEGARes database[9]. MEGARes includes ∼8,000 AMR genes and variants organized in a multi-level hierarchical ontology in the form of a directed acyclic graph, comprising four compound types, 57 classes, 220 mechanisms, and 1,345 groups. This structure ensures that two higher level ranks are not linked to the same lower level rank, and univocity in sequence classification. AMRPlusPlus aligns all reads to MEGARes using the BWA[23], retaining AMR genes with a coverage of at least 80%. Low-quality and low-depth alignments are filtered through the Resistome Analyzer and the Rarefaction Analysis modules, respectively.

Meta-MARC is a machine-learning model based on an ensemble of hierarchical hidden Markov models (HMMs). Each HMM is trained on a group of genes clustered from MEGARes. A classification is performed by aggregating predictions from the lowest level of the MEGARes annotation hierarchy towards the highest level, although there is not always a complete match with the MEGARes ontology due to gene aggregation/split. Meta-MARC provides a three-model ensemble (model groups I-III). Group I models are based on AMR sequences clusters containing more than two unique sequences for each single type of AMR; Group II expands group I and includes genes carrying AMR variants due to single nucleotide polymorphisms. Group III includes all of groups I and II, plus additional sequences obtained by aligning MEGARes genes against the National Center for Biotechnology Information (NCBI) GenBank using the Basic Local Alignment Search Tool (BLAST) and retaining highly similar sequences.

KARGA is an alignment-free tool. It uses sequenced gene *k*-mers, storing the whole k-mer spectrum—i.e., all distinct *k*-mers—both in forward- and reverse-strand from any given reference AMR database. To classify a new sequence, KARGA calculates its *k*-mer spectrum and compares it with the AMR database spectrum. To avoid false positives, KARGA calculates an empirical distribution of matches between randomly generated *k*-mers and the AMR database, approximating a theoretical Markovian distribution, finding an optimal threshold based on query length, *k* value, and the database spectrum. A probabilistic scoring manages multiple gene hits. For this study we used MEGARes, which was also employed in the original KARGA publication [13].

DeepARG is a two-step method that combines read alignment and convolutional deep learning networks. In the first step, an input sequence is translated to amino acids, then aligned to a custom AMR database, which was created by merging the Comprehensive Antibiotic Resistance database (CARD)[5], Antibiotic Resistance Genes Database (ARDB)[6], and manually curated AMR sequences from the Universal Protein Resource (UNIPROT). If the sequence aligns to the custom database, it is passed on to the second step where the deep learning module predicts the AMR category. Of note, the DeepARG classification output does not follow either MEGARes or CARD ontology, but it is a customized set of thirty AMR categories. Deeparg features two working modes, one for long reads and one for short reads.

ResFinder (v.4.0) is a *k*-mer based approach based on Python 3 scripts, that can process both sequence reads and assembled contigs/genomes. The Resfinder *k*-mer engine is based on KMA[24]. Briefly, KMA implements a heuristic *k*-mer matching score with a threshold to accept query sequences for subsequent alignment. Seeds of the identified *k*-mers are used to guide a modified Needleman-Wunsch alignment, which includes a score-based early stop. An additional scoring system, ConClave [24], is then used to resolve tied alignments on redundant sequences and assemble the final output. Notably, bacterial species can be specified by the user in the input, thus customizing the output results for a subset of species-specific resistances.

1.2 Study selection, data set collation, quality control, and evaluation

We performed a literature search AMR sequencing studies on PubMed Central based on keywords and MESH terms related to AMR (see supplementary material for complete list). We then selected studies with the goal of obtaining a data set of at least 500 isolates according to the following criteria: AMR-focused; clinical setting; published within the last seven years (2014-2021); sequenced using Illumina platform; available NCBI BioProject and/or Accession number/code identifier; at least 25 paired-end experiments available in NCBI Sequence Read Archive (SRA); and available AMR resistance profiles determined by phenotypic AST. All FASTQ files were processed with Trimmomatic v.0.32, using all Illumina adapters, and the following parameters: LEADING=3, TRAILING=3 SLIDINGWINDOW=4:15, MINLEN=36. Unpaired reads were discarded. We considered isolates as resistant if they were marked resistant (R), intermediate (I) or susceptible dose dependent (SDD) and sensitive if they were marked sensitive (S) in their source paper. An isolate was considered resistant or susceptible to an antibiotic class if it was marked as resistant or sensitive, respectively to at least one antibiotic within that antibiotic class.

We used the CARD and MEGARes ontologies to link antibiotics to their AMR classes, and considered only the classes that could be predicted by all the tools included in this study. Consistency adjustments of AMR labeling among different algorithms due to different ontology terms were curated by hand (for example, the quinolone DeepARG category corresponds to the fluoroquinolone class used by the other methods). Each isolate is labeled as resistant or susceptible to specific AMR classes. Therefore, we could label isolates as positive (resistant) and negative (susceptible) with respect to each AMR class. To evaluate the performance of the methods, we considered Sensitivity (Sens, or true positive rate), Specificity (Spec, or true negative rate), Balanced Accuracy (BalAcc, the mean of Sens and Spec), and f_1 score, which is the harmonic mean between precision (positive predicted value) and recall (Sens).

1.3 Software and parameter setup

AMRPlusPlus was run with its default parameters. DeepARG was run in short read mode, using the recommended threshold probability of 0.8 for read classification, and the rest of the parameters were set to default. Meta-MARC

was ran specifying paired end input, and model group III, with other parameters set to default. KARGA was ran with its default parameters (k had been previously optimized), filtering AMR genes with coverage below 80% as recommended. Resfinder was used with default parameters.

2 Results

2.1 Data set characteristics, spatio-temporal and species distributions

Five-hundred-eighty-five isolates from six sources (here labeled as S1-S6) met all the study selection criteria. In summary, Weingarten et al. (S1) performed whole genome sequencing on 108 clinical isolates containing carbapenemase-producing organisms (CPOs) from a clinical center in Bethesda, Maryland, USA [25]. Runcharoen et al. (S2) analyzed the relationship between clinical and environmental *Klebsiella pneumoniae* strains, performing whole genome sequencing and phylogenetic analysis of 77 isolates sampled from a hospital, its sewers, and the surrounding canals and farms within a 20-km radius in Thailand [26]; we considered only hospital-related isolates in our analysis. Davies et al. (S3) performed genome sequencing and phylogenetic analysis of 141 clinical isolates from patients, 58 presenting with scarlet fever and 83 with other clinical presentations from Hong Kong, Australia, United States, and Mainland China [27]. Croucher et al. (S4) performed whole genome sequencing and phylogenetic analysis of 189 clinical isolates from twelve countries from 1988 to 2009, discussing the potential relationship between antibiotic dispensing prevalence and antibiotic resistance profiles [28]. Alonos-del Valle et al. (S5) analyzed the antibiotic resistance profiles of 50 gut isolates from patients in a hospital in Madrid, Spain, comparing sample-originated resistance profiles to those produced by introducing a carbapenem-resistance plasmid into each enterobacterial isolate; we considered only sample-originated resistance profiles [29]. Pesesky et al. (S6) predicted antibiotic susceptibility of 78 de-identified patient samples from clinical bacterial biobanks in Rawalpindi and Islamabad, Pakistan and from Saint Louis, Missouri, USA. Enterobacteriaceae isolates, which had been previously sequenced, were analyzed using two genotypic computational algorithms and the results were compared to previously identified phenotypic AST profiles [30]. A more detailed description of the data sources and filtering used to assemble them for this study is provided in the Supplementary Methods.

According to the AMR ontology linkage by MEGARes and CARD defined in the methods, and based on the phenotypic test determined resistance profiles of the study isolates, the following classes are retained in the analysis: aminoglycosides (amikacin, tobramycin, and gentamicin); betalactamases (amoxicilin/clavulanic acid, ampicillin, aztreonam, cefalotin, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, cefuroxime/axetil, doripenem, ertapenem, imipenem, meropenem, penicillin, pipercillin/tazobactam); fluoroquinolones (ciprofloxacin, levofloxacin); glycopeptides (vancomycin); macrolide, lincosamide and streptogramin –MLS– (clindamycin, erythromycin); phenicols (chloramphenicol); sulfonamides (trimethoprim/sulfamethoxazole); tetracyclines (doxycycline, tigecycline, tetracycline); and diaminopyrimidine (trimethoprim, trimethoprim/sulfamethoxazole). The isolates resistant to trimethoprim/sulfamethoxazole were considered resistant to both sulfonamides and diaminopyrimidine, while the susceptible ones were not considered, and the resistance to individual trimethoprim and sulfamethoxazole were not measured.

Tables 2 and 3 summarize the characteristics of each study and per-AMR-class isolates details, respectively. More details are available in the Supplementary Methods, and in Supplementary Tables S1 and S2.

The data sets present highly heterogeneous per-class geographical, temporal, and bacterial distributions. To assess distribution shifts and putative bias, we performed tests for equal proportions of AST resistance by country of origin, year of collection, and genus. Results indicate an extreme heterogeneity for at least one of the three domains for each AMR class, with the exclusion of diaminopyrimidines. More specifically, stratified resistance prevalence exhibited wide ranges for the following AMR classes: aminoglycosides (country [0.14, 0.72], year [0, 0.85], and genus [0, 1]); betalactamases (country [0, 1], year [0, 1], and genus [0.25, 1]); fluoroquinolones (year [0.28, 1] and genus [0, 1]); MLS (year [0, 1]); phenicols (country [0.23, 0.87], temporal [0, 1], and genus [0, 0.89]); and tetracyclines (year [0, 1]). Nonetheless, the odds-ratio (OR) ranges for AMR prevalence shift across calendar years did not indicate a large effect size, varying between 0.98 and 1.4, with five out of seven ORs being larger than 1, suggesting a slight shift towards increased resistance per more recent calendar year. (Only seven classes have both resistant and susceptible isolates.)

				Data Obtained From NCBI SRA Run Selector	
	Publication Year	**Bioproject(s)**	**Isolates***	**Country**	**Bacterial Species (# of isolates)**
S1	2018	PRJNA430442	142	USA	Achromobacter sp. (2) Acinetobacter baumannii (2) Acinetobacter calcoaceticus/baumannii complex sp. (1) Acinetobacter sp. (4) Aeromonas hydrophila (3) Aeromonas sp. (10) Citrobacter freundii (1) Citrobacter freundii complex sp. (13) Citrobacter sp. (2) Enterobacter cloacae (1) Enterobacter cloacae complex sp. (19) Enterobacteriaceae bacterium (5) Escherichia coli (8) Escherichia sp. (1) Klebsiella aerogenes (2) Klebsiella oxytoca (15) Klebsiella pneumoniae (23) Klebsiella pneumoniae subsp. Pneumoniae (2) Leclercia sp. (11) Pantoea sp. (5) Pseudomonas sp. (2) Serratia sp. (10)
S2	2017	PRJEB11403	50	Thailand	Klebsiella pneumoniae (45) Klebsiella quasipneumoniae (5)
S3	2014	PRJEB2657, PRJEB2589	133	Hong Kong	Streptococcus pyogenes (133)
S4	2014	PRJEB2255	140	Iceland Peru Portugal Thailand	Streptococcus pneumoniae (140)
S5	2021	PRJNA641166	47	Spain	Escherichia coli (23) Klebsiella pneumoniae (20) Klebsiella quasivariicola (2) Klebsiella quasipneumoniae (2)
S6	2016	PRJNA261540	73	Pakistan USA	Escherichia coli (33) Klebsiella pneumoniae (28) Enterobacter cloacae (8) Klebsiella aerogenes (4)

Table 2: Summary of sources included in our AMR benchmarking study. For isolate details (*) and additional data pre-processing, see Supplementary Table S1 and Supplementary Methods for filters applied to assemble data set for this study.

Antibiotic Class	Resistant Isolates	Sensitive Isolates	Most Represented Country	Most Prevalent Genus
Aminoglycosides	181 (58%)	131 (42%)	USA (53%)	Klebsiella (47%)
betalactamases	326 (66%)	166 (34%)	USA (33%)	Streptococcus (37%)
Fluoroquinolones	146 (55%)	119 (45%)	USA (62%)	Klebsiella (47%)
Glycopeptides	0 (0%)	133 (100%)	Hong Kong (100%)	Streptococcus (100%)
MLS	217 (81%)	51 (19%)	Hong Kong (50%)	Streptococcus (100%)
Phenicols	199 (63%)	119 (37%)	Iceland (36%)	Streptococcus (42%)
Sulfonamides	141 (100%)	0 (0%)	USA (72%)	Klebsiella (35%)
Tetracyclines	301 (77%)	88 (23%)	Hong Kong (34%)	Streptococcus (68%)
Diaminopyrimidine (Trimethoprim)	180 (94%)	11 (6%)	USA (53%)	Klebsiella (52%)

Table 3: Resistant and sensitive isolates, most represented country, and most prevalent genus per AMR class.

2.2 Computational determination of AMR, prediction performance, and agreement among algorithms

All 585 isolates were processed by each AMR computational tool. The prediction performances are summarized in Table 4. Overall, ResFinder yields the highest average BalAcc across all classes, 0.87 (InterQuartile Range, IQR 0.63, 0.89), followed by KARGA with 0.83 (0.73, 0.84), AMRPlusPlus with 0.8 (0.51, 0.89), DeepARG with 0.55 (0.5, 0.62), and Meta-MARC with 0.5 (0.5, 0.62). Comparing the per-AMR-class BalAcc in the top three methods, the null hypothesis that one distribution is greater than the other can not be rejected (Wilcoxon rank sum test p-value of 0.74 and 0.34 for, respecitvely, Resfinder versus KARGA and Resfinder versus AMRPlusPlus). We observe a wide per-AMR-class heterogeneity, without any method performing superior to the others on all the classes. KARGA is the most robust according to quartile coefficient of dispersion (0.07 for KARGA, 0.17 for ResFinder). For aminoglycosides and fluoroquinolones, all algorithms perform poorly, with the best BalAcc achieved by KARGA (0.66 and 0.58, respectively) and ResFinder (0.64 and 0.61, respectively). In betalactamases, the best algorithm is AMRPlusPlus (BalAcc 0.9); other algorithms perform in the [0.83-0.89] range, with the exception of ResFinder (0.5). In MLS, ResFinder and KARGA achieve a BalAcc of 0.93 and 0.83, respectively, while other algorithms are limited to the [0.4, 0.57] range. In phenicols, tetracyclines, and diaminopyrimidines, Resfinder, KARGA, and AMRPlusPlus achieve BalAccs in the [0.8, 0.91] range, while other algorithms are limited to the [0.5, 0.72] range. In glycopeptides, where our data set consists of susceptible isolates only, all the instances are correctly classified by each algorithm. In sulfonamides, where our data set presents only resistant isolates, ResFinder achieves the best result with Sens of 1, while the other algorithms produced results in the range [0.84-0.97].

Next, we evaluated the prediction concordance between each algorithm pair, which is illustrated in Figure 1. AMRPlusPlus, KARGA, and Resfinder cluster together, and exhibit moderate to high pairwise correlations, ranging between 0.62 and 0.72. Meta-MARC and DeepARG exhibit a lower mutual correlation (0.56), and are not well-correlated with the other methods, with a correlation ranging from 0.27 to 0.55.

To further investigate whether there are differences among algorithms even when they are concordant in overall resistance determination (e.g., if they identify two different AMR genes or mechanisms) we look at the most represented AMR groups by each algorithm, according to the MEGARes ontology (i.e., 42 groups for aminoglycosides, 221 for betalactamases, 17 for fluoroquinolones, 68 for glycopeptides, 83 for MLS, 18 for phenicols, 7 for sulfonamides, 62 for tetracyclines, and 11 for trimethoprim). Since Resfinder has a different categorization, only AMRPlusPlus, KARGA, and Meta-MARC can be compared. Note that the group level is the finest AMR functional granularity that can be reached with these algorithms (AMRPlusPlus and KARGA can give gene predictions, but Meta-MARC cannot). Results are shown in Figure 2. Interestingly, even algorithms with higher correlation can identify very different groups at the base of the predicted resistance. For instance, in the fluoroquinolone class, KARGA finds primarily PATB and PATA, while AMRPlusPlus finds GYRA and PARC; in sulfonamides, FOLP is strongly predicted by both AMRPlusPlus and Meta-MARC, but not KARGA; on the other hand, only KARGA predicts SULI in a large number of isolates. Some of the differences are explainable by the

Antibiotic Class	Algorithm	Sens ± SE	Spec ± SE	F-score ± SE	BalAcc ± SE
Aminoglycosides	AMRPlusPlus	0.99 ± 0.01	0	0.64 ± 0.03	0.5 ± 0.03
	DeepARG	1	0	0.64 ± 0.03	0.5 ± 0.03
	Meta-MARC	0.99 ± 0.01	0.02 ± 0.01	0.64 ± 0.03	0.5 ± 0.03
	KARGA	0.98 ± 0.01	0.35 ± 0.03	0.73 ± 0.03	**0.66 ± 0.03**
	Resfinder	0.99 ± 0.01	0.30 ± 0.03	0.71 ± 0.01	**0.64 ± 0.02**
betalactamases	**AMRPlusPlus**	1	0.8 ± 0.03	0.95 ± 0.01	**0.9 ± 0.02**
	DeepARG	0.87 ± 0.02	0.8 ± 0.03	0.89 ± 0.02	0.84 ± 0.02
	Meta-MARC	0.98 ± 0.01	0.8 ± 0.03	0.94 ± 0.01	**0.89 ± 0.02**
	KARGA	0.86 ± 0.02	0.81 ± 0.03	0.88 ± 0.02	0.83 ± 0.02
	Resfinder	1	0	0.8 ± 0.03	0.5 ± 0.03
Fluoroquinolones	AMRPlusPlus	0.97 ± 0.01	0.08 ± 0.02	0.72 ± 0.03	0.53 ± 0.03
	DeepARG	1	0	0.71 ± 0.03	0.5 ± 0.03
	Meta-MARC	0.98 ± 0.01	0.02 ± 0.01	0.7 ± 0.03	0.5 ± 0.03
	KARGA	0.6 ± 0.03	0.55 ± 0.03	0.61 ± 0.03	**0.58 ± 0.03**
	Resfinder	0.92 ± 0.02	0.31 ± 0.03	0.74 ± 0.03	**0.61 ± 0.03**
Glycopeptides	AMRPlusPlus	NA	1	NA	NA
	DeepARG	NA	1	NA	NA
	Meta-MARC	NA	1	NA	NA
	KARGA	NA	1	NA	NA
	Resfinder	NA	1	NA	NA
MLS	AMRPlusPlus	1	0	0.89 ± 0.02	0.5 ± 0.03
	DeepARG	0.87 ± 0.02	0.27 ± 0.03	0.85 ± 0.02	0.57 ± 0.03
	Meta-MARC	0.46 ± 0.03	0.33 ± 0.03	0.57 ± 0.03	0.4 ± 0.03
	KARGA	1	0.67 ± 0.03	0.96 ± 0.01	0.83 ± 0.02
	Resfinder	1	0.86 ± 0.02	0.98 ± 0.01	**0.93 ± 0.02**
Phenicols	AMRPlusPlus	0.93 ± 0.02	0.72 ± 0.03	0.88 ± 0.02	0.82 ± 0.02
	DeepARG	0.82 ± 0.02	0.29 ± 0.03	0.73 ± 0.03	0.55 ± 0.03
	Meta-MARC	0.33 ± 0.03	0.71 ± 0.03	0.44 ± 0.03	0.52 ± 0.03
	KARGA	0.86 ± 0.02	0.85 ± 0.02	0.88 ± 0.02	**0.85 ± 0.02**
	Resfinder	0.88 ± 0.02	0.88 ± 0.02	0.9 ± 0.02	**0.88 ± 0.02**
Sulfonamides	AMRPlusPlus	0.96 ± 0.01	NA	0.98 ± 0.01	NA
	DeepARG	0.92 ± 0.02	NA	0.96 ± 0.01	NA
	Meta-MARC	0.97 ± 0.01	NA	0.99 ± 0.01	NA
	KARGA	0.84 ± 0.02	NA	0.92 ± 0.02	NA
	Resfinder	1	NA	1	NA
Tetracyclines	**AMRPlusPlus**	0.9 ± 0.02	0.85 ± 0.02	0.93 ± 0.02	**0.88 ± 0.02**
	DeepARG	0.9 ± 0.02	0.44 ± 0.03	0.87 ± 0.02	0.67 ± 0.03
	Meta-MARC	0.99 ± 0.01	0.45 ± 0.03	0.92 ± 0.02	0.72 ± 0.03
	KARGA	0.71 ± 0.03	0.9 ± 0.02	0.81 ± 0.03	0.8 ± 0.03
	Resfinder	0.94 ± 0.02	0.81 ± 0.03	0.94 ± 0.02	**0.87 ± 0.02**
Diaminopyrimidines (Trimethoprim)	**AMRPlusPlus**	0.91 ± 0.02	0.91 ± 0.02	0.95 ± 0.01	**0.91 ± 0.02**
	DeepARG	0	1	NA	0.5 ± 0.03
	Meta-MARC	0.91 ± 0.02	0.09 ± 0.02	0.93 ± 0.02	0.5 ± 0.03
	KARGA	0.9 ± 0.02	0.91 ± 0.02	0.94 ± 0.01	**0.9 ± 0.02**
	Resfinder	0.91 ± 0.02	0.91 ± 0.02	0.95 ± 0.01	**0.91 ± 0.02**

Table 4: Classification performance for all methods on S1-S6 data sets (585 isolates), stratified per AMR class. Instances in bold show the top-performing methods whose balanced accuracy overlaps according to the standard error (SE).



Figure 1: Heatmap of Pearson's correlations between AMR classifiers' predictions run on S1-S6 data sets (585 isolates).

fact that AMRPlusPlus and Meta-MARC are able to flag chromosomal genes that induce antibiotic resistance through point mutations, e.g., the GYRA topoisomerase enzyme subunit, while KARGA does not (because they need secondary confirmation of the point mutations). Another reason is that the presence of more than one gene could be needed for resistance, and the algorithms might identify one or the other, but not both. Finally, some genes could be very similar, leading to uncertainty in the identification and different frequencies in gene findings by different algorithms. Of note, Meta-MARC clusters very similar genes, and only one representative is used.

3 Discussion

Algorithm performance. Overall, all the methods except KARGA had a high number of false positive predictions, i.e., predicting the positive (resistant) class on negative (susceptible) isolates. In some specific cases, *all*, or almost all, the isolates for a class were classified as positive, i.e., betalactamases for ResFinder; aminoglycosides and fluoroquinolones for AMRPlusPlus, Meta-MARC, and DeepARG; and MLS for AMRPlusPlus.

We note that the classification results of DeepARG are given per read, i.e., the AMR class label is not predicted at the isolate level. Therefore, results must be aggregated, and a threshold applied. To better understand how this affected results, in a sensitivity analysis, we considered two additional approaches: (1) using a higher threshold than the default probability (0.8) of DeepARG; and (2) to require a minimum number of reads to support AMR determination at the isolate level. A threshold of up to 0.99 did not change the main results, i.e., in case of positive classification, there was always at least one read with a predicted probability of 0.99 or more. For the second strategy, to label the whole isolate as resistant, we evaluated a grid of thresholds with a minimum number of resistant reads, i.e., 10, 100, 1000, and 10000. However, none of the values improved results consistently for all classes. For example, in the case of aminoglycosides, a threshold of 1000 led to the best BalAcc (0.53 versus the default of 0.5); the best threshold for the in betalactamase class was 1, all other values degraded the performance. In general, threshold optimization could lead to performance improvement, but we must note that: (a) there is not a one-size-fits-all solution, and the threshold must be optimized per AMR class; (b) this post-hoc adjustment may lead to overfitting, as the optimal threshold should be part of the training phase, and testing should be done on unseen data; (c) even optimizing the threshold, the results do not reach the performance of the top three algorithms in this study. Detailed results of the threshold-dependent predictions are provided in the

Figure 2: Per-class MEGARes AMR group prediciton analysis on AMRPlusPlus, Meta-MARC, and KARGA. We measured the number of isolates predicted as positive to each group (regardless the phenotype label), per class, indicated on the X and Y axes of the panels. All 585 isolates for each class are compared. We report the names of the top groups depending on the per-class group numerosity, as follows: top five per method if there are more than 99 groups in the class; top three if 99 to 25; top two if 24-15; and top one for less than 15 groups in the class. Of note, isolates without an associated glycopeptide AMR profile, are found resistant to glycopeptide (more than a hundred by Meta-MARC and more than thirty by KARGA and ResFinder).

Supplementary Table S3. As a last note for DeepARG, the radical difference in prediction for diaminopyrimidines, when compared to other algorithms, could be due to absence of specific trimethoprim sequences that are instead present in MEGARes.

In summary, we observed that no one algorithm provides outstanding results in all of the considered AMR classes in terms of balanced accuracy, and the same holds for the f_1 measure. Yet on average they all perform well. Although encouraging, these results are still far from a near-perfect classification that would be needed to include them in clinical practice as substitutes to AST.

Distribution shift and bias. All high-throughput AMR prediction algorithms, based on sequence alignment, *k*-mers, or machine learning, are trained on an established ground truth. Training data sets include well-characterized, laboratory-confirmed AMR genes, such as MEGARes[9] or CARD[5], or collections of whole genomes with associated AST phenotypes, as in PATRIC[7]. They are the result of a coordinated effort by the scientific community to collect and standardize AMR knowledge, but can be subject to several types of bias, sampling in primis[10, 18]. For example, a genus or species can be over-represented; distribution of samples over time are not uniform; and there is substantial geographical bias (by country or samples within localized outbreaks). Species distribution shifts can be common even within related clinical settings, e.g. in infections whose source/colonization origin is different or when treatment protocols change over time. Evidence of bias across genus, temporal, and geographical representation was found in PATRIC, and it was shown that such bias affects discriminative ability of AMR machine learning predictions by 5% [18]. For most of the AMR classes in our set we found strong geographical and per-genus distribution shifts. We consider this finding a further indication that these sources of bias should be accounted for when collecting data used as a reference or training set for AMR prediction algorithms.

Problems with ground truth. Similar to standardized AST methods, there is need to develop standardized AMR bioinformatics protocols and evaluation benchmarks, so that results from different studies can be put together and used for training and validation. So far, the Food and Drug Administration does not provide standardized regulatory guidelines for metagenomic diagnostic tests[3]. A second major obstacle to comparing the performances of different AMR classification tools is that they can be based on different AMR ontologies –albeit an output match is possible for most antibiotic classes at different granularity levels. We must note that CARD and MEGARes ontologies are designed to organize genes and resistance mechanisms, thus they are well suited for studies on metagenomics and ecology, but less for clinical studies where single species are cultured and tested against antibiotics. Although there are other off-the-shelf tools that predict directly AST from genotypes, they need assembled and finished genomes, which is a non-trivial (and time consuming) step in the analytics pipeline, while all the methods used here accept raw short read data.

The high-throughput AMR prediction algorithms we examined provide mostly a per-AMR-class prediction, with a few exceptions, e.g., MEGARes-based output below the class level, such as the specific penicillin binding protein mechanism. However, the isolates we consider have been tested only against some specific antibiotics within a class. In the case of resistant isolates, this is not necessarily a problem. For example, if an isolate is resistant to ampicillin, since it is resistant to at least one antibiotic of the betalactamase class, we can consider it resistant to the whole class and the algorithmic recommendation would be not to use betalactamases to address this particular infection. This assumption does not hold, however, for susceptibility. If another isolate is, for example, susceptible to ampicillin, we cannot label it with certainty as susceptible to all betalactamases –in order to do so, we should in fact test it extensively against a large fraction (ideally, all) of the betalactamases antibiotics. This poses another a priori problem with the ground truth, namely the fact that susceptible instances might be falsely labeled as they were not tested against all antibiotics of each specific class. It is however unrealistic to expect from observational studies, such as the ones we used to assemble the data set used for this work, to explicitly test resistance against an exhaustive range of antibiotic classes and molecules. Even large genome collections show how most of the species versus antibiotic combinations have few to no records[7, 10]. Another problem in assessing the correctness of the predictions is that the AMR framework description can include labels that are not informative enough to infer the antibiotic resistance at the class level. This is the case, for example, of MEGARes multi-compound or multi-drug classes, or the DeepARG 'unknown' category. Such annotations are not suitable for a direct integration within clinical practice, as they do not provide precise indications to which AMR classes the sample or isolate is

resistant.

4 Conclusions

Current computational tools for AMR characterization from high-throughput sequencing data show promising results, but do not appear ready for application in clinical settings. There are obstacles that go beyond algorithmic development and relate to bias in data as well as issues with ground truth and ontology, hampering algorithm development and benchmarking. Therefore, we make a call to develop prospective studies designed with the specific intent of training and validating computational AMR tools, i.e., with explicit determination of possible sources of bias, comprehensive characterization of AST profiles, and linkage with at least one of the current ontologies. These data sets would then constitute the gold standard ground truth to build AMR detection algorithms on.

5 Key points

- Current computational tools for AMR characterization from high throughput sequencing data show promising results but do not seem ready for application in clinical settings.
- Each method provides a wide range of performances over the considered AMR classes; no method seems to provide the best results in all the classes.
- The major roadblocks towards a realistic bench-to-bedside implementation are:
  - The presence of bias, such species, geographical, and temporal biases in the reference/training data sets
  - The need to establish a per AMR-class ground truth by testing an extensive portion of the antibiotics (ideally, all of them) for each specific antibiotic class
  - Absence of standardization in both AST and AMR ontologies

Funding

This work was in part supported by US grants NIH NIAID R01AI141810, NSF SCH 2013998, and USDA AFRI grant no. 2019-67017-29110.

Acknowledgment

The authors want to thank Marco Oliva, Ilya B. Slizovskiy, and Daniele N. Cudin for the productive and deep conversations.

References

[1] P. Dadgostar, "Antimicrobial resistance: implications and costs," *Infection and drug resistance*, vol. 12, p. 3903, 2019.

[2] A. Chokshi, Z. Sifri, D. Cennimo, and H. Horng, "Global contributors to antibiotic resistance," *Journal of global infectious diseases*, vol. 11, no. 1, p. 36, 2019.

[3] A. Dulanto Chiang and J. P. Dekker, "From the pipeline to the bedside: advances and challenges in clinical metagenomics," *The Journal of infectious diseases*, vol. 221, no. Supplement_3, pp. S331–S340, 2020.

[4] V. Wuthiekanun, P. Amornchai, D. H. Paris, S. Langla, J. Thaipadunpanit, W. Chierakul, L. D. Smythe, N. J. White, N. P. Day, D. Limmathurotsakul, *et al.*, "Rapid isolation and susceptibility testing of leptospira spp. using a new solid medium, lvw agar," *Antimicrobial agents and chemotherapy*, vol. 57, no. 1, pp. 297–302, 2013.

[5] B. P. Alcock, A. R. Raphenya, T. T. Lau, K. K. Tsang, M. Bouchard, A. Edalatmand, W. Huynh, A.-L. V. Nguyen, A. A. Cheng, S. Liu, *et al.*, "Card 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database," *Nucleic Acids Research*, vol. 48, no. D1, pp. D517–D525, 2020.

[6] B. Liu and M. Pop, "Ardb—antibiotic resistance genes database," *Nucleic Acids Research*, vol. 37, no. suppl_1, pp. D443–D447, 2009.

[7] J. J. Davis, A. R. Wattam, R. K. Aziz, T. Brettin, R. Butler, R. M. Butler, P. Chlenski, N. Conrad, A. Dickerman, E. M. Dietrich, *et al.*, "The patric bioinformatics resource center: expanding data and analysis capabilities," *Nucleic Acids Research*, vol. 48, no. D1, pp. D606–D612, 2020.

[8] J. J. Davis, S. Boisvert, T. Brettin, R. W. Kenyon, C. Mao, R. Olson, R. Overbeek, J. Santerre, M. Shukla, A. R. Wattam, *et al.*, "Antimicrobial resistance prediction in patric and rast," *Scientific Reports*, vol. 6, p. 27930, 2016.

[9] E. Doster, S. M. Lakin, C. J. Dean, C. Wolfe, J. G. Young, C. Boucher, K. E. Belk, N. R. Noyes, and P. S. Morley, "Megares 2.0: a database for classification of antimicrobial drug, biocide and metal resistance determinants in metagenomic sequence data," *Nucleic Acids Research*, vol. 48, no. D1, pp. D561–D569, 2020.

[10] M. VanOeffelen, M. Nguyen, D. Aytan-Aktug, T. Brettin, E. M. Dietrich, R. W. Kenyon, D. Machi, C. Mao, R. Olson, G. D. Pusch, *et al.*, "A genomic data resource for predicting antimicrobial resistance from laboratory-derived antimicrobial susceptibility phenotypes," *Briefings in Bioinformatics*, 2021.

[11] S. M. Lakin, A. Kuhnle, B. Alipanahi, N. R. Noyes, C. Dean, M. Muggli, R. Raymond, Z. Abdo, M. Prosperi, K. E. Belk, *et al.*, "Hierarchical hidden markov models enable accurate and diverse detection of antimicrobial resistance sequences," *Communications Biology*, vol. 2, no. 1, pp. 1–11, 2019.

[12] G. Arango-Argoty, E. Garner, A. Pruden, L. S. Heath, P. Vikesland, and L. Zhang, "Deeparg: a deep learning approach for predicting antibiotic resistance genes from metagenomic data," *Microbiome*, vol. 6, no. 1, pp. 1–15, 2018.

[13] M. Prosperi and S. Marini, "Karga: Multi-platform toolkit for k-mer-based antibiotic resistance gene analysis of high-throughput sequencing data," in *2021 IEEE EMBS International Conference on Biomedical and Health Informatics (BHI)*, pp. 1–4, IEEE, 2021.

[14] E. Ruppé, A. Ghozlane, J. Tap, N. Pons, A.-S. Alvarez, N. Maziers, T. Cuesta, S. Hernando-Amado, I. Clares, J. L. Martínez, *et al.*, "Prediction of the intestinal resistome by a three-dimensional structure-based method," *Nature Microbiology*, vol. 4, no. 1, pp. 112–123, 2019.

[15] S. Marini, M. Oliva, I. B. Slizovskiy, N. R. Noyes, C. Boucher, and M. Prosperi, "Exploring prediction of antimicrobial resistance based on protein solvent accessibility variation," *Frontiers in Genetics*, vol. 12, p. 26, 2021.

[16] M. W. Pesesky, T. Hussain, M. Wallace, S. Patel, S. Andleeb, C.-A. D. Burnham, and G. Dantas, "Evaluation of machine learning and rules-based approaches for predicting antimicrobial resistance profiles in gram-negative bacilli from whole genome sequence data," *Frontiers in microbiology*, vol. 7, p. 1887, 2016.

[17] R. M. Doyle, D. M. O'Sullivan, S. D. Aller, S. Bruchmann, T. Clark, A. C. Pelegrin, M. Cormican, E. D. Benavente, M. J. Ellington, E. McGrath, *et al.*, "Discordant bioinformatic predictions of antimicrobial resistance from whole-genome sequencing data of bacterial isolates: An inter-laboratory study," *Microbial Genomics*, vol. 6, no. 2, 2020.

[18] M. Prosperi, S. Marini, C. Boucher, and J. Bian, "Assessing putative bias in prediction of anti-microbial resistance from real-world genotyping data under explicit causal assumptions," *arXiv preprint arXiv:2107.03383*, 2021.

[19] M. Prosperi, T. Azarian, J. A. Johnson, M. Salemi, F. Milicchio, and M. Oliva, "Unexpected predictors of antibiotic resistance in housekeeping genes of staphylococcus aureus," in *Proceedings of the 10th ACM International Conference on Bioinformatics, Computational Biology and Health Informatics*, pp. 259–268, 2019.

[20] K. A. Tagg, N. J. Jeoffreys, D. L. Couldwell, J. A. Donald, and G. L. Gilbert, "Fluoroquinolone and macrolide resistance-associated mutations in mycoplasma genitalium," *Journal of clinical microbiology*, vol. 51, no. 7, pp. 2245–2249, 2013.

[21] E. Montassier, R. Valdés-Mas, E. Batard, N. Zmora, M. Dori-Bachash, J. Suez, and E. Elinav, "Probiotics impact the antibiotic resistance gene reservoir along the human gi tract in a person-specific and antibiotic-dependent manner," *Nat Microbiol*, no. 6, pp. 1043–1054, 2021.

[22] V. Bortolaia, R. S. Kaas, E. Ruppe, M. C. Roberts, S. Schwarz, V. Cattoir, A. Philippon, R. L. Allesoe, A. R. Rebelo, A. F. Florensa, *et al.*, "Resfinder 4.0 for predictions of phenotypes from genotypes," *Journal of Antimicrobial Chemotherapy*, vol. 75, no. 12, pp. 3491–3500, 2020.

[23] H. Li and R. Durbin, "Fast and accurate long-read alignment with burrows–wheeler transform," *Bioinformatics*, vol. 26, no. 5, pp. 589–595, 2010.

[24] P. T. Clausen, F. M. Aarestrup, and O. Lund, "Rapid and precise alignment of raw reads against redundant databases with kma," *BMC bioinformatics*, vol. 19, no. 1, pp. 1–8, 2018.

[25] R. A. Weingarten, R. C. Johnson, S. Conlan, A. M. Ramsburg, J. P. Dekker, A. F. Lau, P. Khil, R. T. Odom, C. Deming, M. Park, *et al.*, "Genomic analysis of hospital plumbing reveals diverse reservoir of bacterial plasmids conferring carbapenem resistance," *MBio*, vol. 9, no. 1, pp. e02011–17, 2018.

[26] C. Runcharoen, D. Moradigaravand, B. Blane, S. Paksanont, J. Thammachote, S. Anun, J. Parkhill, N. Chantratita, and S. J. Peacock, "Whole genome sequencing reveals high-resolution epidemiological links between clinical and environmental klebsiella pneumoniae," *Genome medicine*, vol. 9, no. 1, pp. 1–10, 2017.

[27] M. R. Davies, M. T. Holden, P. Coupland, J. H. Chen, C. Venturini, T. C. Barnett, N. L. B. Zakour, H. Tse, G. Dougan, K.-Y. Yuen, *et al.*, "Emergence of scarlet fever streptococcus pyogenes emm 12 clones in hong kong is associated with toxin acquisition and multidrug resistance," *Nature genetics*, vol. 47, no. 1, pp. 84–87, 2015.

[28] N. J. Croucher, W. P. Hanage, S. R. Harris, L. McGee, M. van der Linden, H. de Lencastre, R. Sá-Leão, J.-H. Song, K. S. Ko, B. Beall, *et al.*, "Variable recombination dynamics during the emergence, transmission and 'disarming'of a multidrug-resistant pneumococcal clone," *BMC biology*, vol. 12, no. 1, pp. 1–15, 2014.

[29] A. Alonso-del Valle, R. León-Sampedro, J. Rodríguez-Beltrán, J. DelaFuente, M. Hernández-García, P. Ruiz-Garbajosa, R. Cantón, R. Peña-Miller, and A. San Millán, "Variability of plasmid fitness effects contributes to plasmid persistence in bacterial communities," *Nature communications*, vol. 12, no. 1, pp. 1–14, 2021.

[30] M. W. Pesesky, T. Hussain, M. Wallace, B. Wang, S. Andleeb, C.-A. D. Burnham, and G. Dantas, "Kpc and ndm-1 genes in related enterobacteriaceae strains and plasmids from pakistan and the united states," *Emerging infectious diseases*, vol. 21, no. 6, p. 1034, 2015.